CasInvent Pharma

CasInvent Pharma was established in 2020 as a spin-off of Masaryk University (MU) in cooperation with the investment partner i&i Prague, s.r.o. (Ltd). The mission of the company is to develop new therapeutic options for the treatment resistant tumors. The CasInvent platform is based on the use of proprietary, best in classhighly selective inhibitors of enzymes belonging to the Casein Kinase 1 (CK1) family that are responsible for the regulation of different cellular mechanisms leading to resistance for targeted therapies.

The CK1 inhibitors were discovered by the research groups of professors Vítězslav Bryja and Kamil Paruch at the Faculty of Science of MU, who have long-term expertise in the research areas of CK1 biology and chemistry of kinase inhibitors, respectively. CasInvent Pharma closely cooperates with these teams in advanced preclinical development of selected substances. The candidate compound is planned to enter clinical trials focused on the treatment of resistance Acute Myeloid Leukemia (AML) and solid tumor indications such as PDAC, TNBC, Melanoma or prostate cancer.